Currently, three drug candidates are targeting the PD-1/PD-L1 pathway in GBM therapy development: Nivolumab (NCT04195139), Durvalumab (NCT02336165), and Cemiplimab (NCT03491683). This evidence concerns the gene CD274 and glioblastoma.